Oricell Therapeutics on Thursday said it has raised $110 million in a pre-initial public offering financing round as it looks to break into international markets. The Shanghai-based company's lead ...

Astellas Pharma will pay Dyno a license fee to use its engineered AAV capsid, as well as possible milestone payments and royalties.

Through a six-month pilot program at Pacific Cancer Care, the firms are assessing if they can improve guidelines-backed ...

The firm also plans to file a clinical trial application for another RNA drug targeting the same liver protein by mid-2026.

Under the expanded collaboration, Gilead will use Tempus' platform to analyze more patient data for oncology drug development and clinical trial design.

NEW YORK – Acurion has raised $4.3 million in seed funding to further establish its OncoGaze digital pathology platform's ability to detect biomarkers from cancer hematoxylin and eosin slides and ...

The firm will use the funds, which now total around $46 million, to advance the CDK2 inhibitor INX-315 in CDK4/6 inhibitor-resistant breast and ovarian cancers.

The firm dosed the first person in a Phase I trial of ALZ-507 in healthy volunteers, which will inform dosing in subsequent Phase II trials.

Funded by the Cancer Grand Challenges initiative, the UK branch of the trial has already enrolled the first patient.